# Bruker

> Bruker is a VC fund in Madison backing Biotechnology and Medical. See 17 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Madison, United States
- Total investments: 17
- Last investment: Sep 2025
- Lead investor: 41%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/bruker-corporation
- X (Twitter): http://twitter.com/bruker
- Website: http://www.bruker.com/
- Facebook: http://www.facebook.com/bruker.corp

Bruker is a VC fund in Madison focused on Biotechnology and Medical. Bruker Corporation is a provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis.

## Contacts

5 contacts available for Bruker. Shizune tracks 11 team members at Bruker. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/bruker?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 13 | 76% |
| Medical | 5 | 29% |
| Health Care | 5 | 29% |
| Health Diagnostics | 4 | 24% |
| Life Science | 3 | 18% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 24% |
| Series B | 4 | 24% |
| Seed | 2 | 12% |
| Corporate Round | 2 | 12% |
| Series C | 1 | 6% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 9 | 53% |
| Switzerland | 2 | 12% |
| France | 1 | 6% |
| Germany | 1 | 6% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Erez Sokolski | Project Manager | 0 | https://shizune.co/investors/profile/erez-sokolski |
| Frank Laukien | President & CEO | 3 | https://shizune.co/investors/profile/frank-laukien |
| Hermann Requardt | Member of the Board of Directors | 0 | https://shizune.co/investors/profile/hermann-requardt |
| Jason Faessler | Vice President, Financial Planning and Analysis | 0 | https://shizune.co/investors/profile/jason-faessler |
| Lance Kuhn | Director Of Customer Service | 0 | https://shizune.co/investors/profile/lance-kuhn |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Mercy BioAnalytics | Mercy BioAnalytics is a biotechnology company that aims to improve and save the lives of people through the early detection of cancer.It has developed a process that uses nano-particles that are extraordinarily abundant in blood and carry information about their parent cell – known as extracellular vesicles, or EVs – to detect stage I cancer.Paul Blavin and Joseph Sedlak founded the Natick, Massachusetts-based company in 2018. | $59M | Series B | Sep 03, 2025 |  |
| Olaris | Olaris is on a mission to revolutionize how diseases are diagnosed and treated. By leveraging our CEREBRO platform (Comprehensive Early Responsive Evaluation of Biomarkers Related to Outcomes), which combines metabolomics and machine learning, we harness the power of the body’s own communication system to discover and develop our pipeline ofmyOLARIS™ precision diagnostics. To learn more, visit https://www.myolaris.com/The company was founded in 2013 and is headquartered in Framingham, Massachusetts. |  | Series B | Apr 08, 2025 |  |
| Terrain Bio | Terrain BioSciences is in the field of RNA-based therapeutics and vaccine development. Leveraging advanced AI and proprietary manufacturing platforms, Terrain BioSciences addresses the challenges of designing, selecting, manufacturing, and delivering optimal RNA sequences. Terrain BioSciences collaborates with over a dozen biotech firms to enhancethe expression, durability, and manufacturability of RNA sequences, significantly accelerating their path to clinical application. With a focus on personalized cancer vaccines and other RNA-based modalities, Terrain BioSciences is at the forefront of the next generation of programmable medicines. | $9M | Seed | Feb 12, 2025 |  |
| PrognomiQ | PrognomiQ is a biotechnology firm that develops test products for the early detection and treatment of cancer and other complex diseases through the power of multi-omics data. | $34.3M | Series D | Nov 05, 2024 |  |
| NovAliX | NovAliX is focusing on the development of enabling chemistry and biophysical technologies to support the pharmaceutical industry's outsourcing needs from discovery to manufacturing.With proprietary SPR technology, X-ray protein crystallography, supramolecular mass spectrometry and chemistry, NovAliX offers comprehensive integrated servicesfor small molecule drug discovery.With advanced NMR technologies, NovAliX provides fine characterization of biologics, thorough analysis of APIs and polymorphism studies to support pharmaceutical development and manufacturing teams. |  | Corporate Round | Aug 07, 2024 |  |
| Tome Biosciences | Tome Biosciences is a biotechnology company that develops programmable gene insertion technology. Using CRISPR, its technologies allow them to insert any genetic sequence of any size at any location into any genome. | $213M | Series A | Dec 12, 2023 |  |
| Mercy BioAnalytics | Mercy BioAnalytics is a biotechnology company that aims to improve and save the lives of people through the early detection of cancer.It has developed a process that uses nano-particles that are extraordinarily abundant in blood and carry information about their parent cell – known as extracellular vesicles, or EVs – to detect stage I cancer.Paul Blavin and Joseph Sedlak founded the Natick, Massachusetts-based company in 2018. | $41M | Series A | Apr 03, 2023 |  |
| KIYATEC | KIYATEC utilizes the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies. Its 3DKUBE technology platform conveniently and cost-effectively incorporates perfusion flow, accommodates all scaffold materials, allows in situ imaging, models complex human biology using segregated cell co‐culture, and is asingle-use disposable. 3DKUBE cell‐based assays leverage these features to create better in vitro prediction of complex biochemical responses in humans, with a focus on the evaluation of drug toxicity and efficacy prior to use in human clinical trials. | $18M | Series C | Dec 12, 2022 |  |
| Haystack Oncology | Haystack Oncology, an oncology company, uses the most recent circulating tumor DNA detection technology to enhance the diagnosis of minimum residual disease and provide superior therapy decision-making information. | $56M | Series A | Nov 16, 2022 |  |
| Navignostics | Our mission is to identify the ideal treatment to battle each cancer patient’s disease and reduce suffering throughout their journey.At Navignostics we characterize tumors using spatial single-cell proteomics. We use our unique capabilities to identify a cancer treatment that will optimally fight each patient’s tumor. We also accelerate cancerdrug development by providing key insights into drug mechanisms and tumor features for companion diagnostic development.Our highly robust and reliable technology and our leading data analytics position us ideally to enable precision cancer diagnostics for patients and to provide services to pharma and biotech partners.This way we help people suffering from cancer by making more drugs available and by finding the right one for every patient. | $7.6M | Seed | Nov 09, 2022 |  |

10 of 17 investments shown.

## Co-investors
- [Catalio Capital Management](https://shizune.co/investors/profile/catalio-capital-management) — VC Fund, 5 deals together
- [LabCorp](https://shizune.co/investors/profile/laboratory-corporation-of-america) — VC Fund, 4 deals together
- [aMoon Fund](https://shizune.co/investors/profile/amoon) — VC Fund, 3 deals together
- [Invus](https://shizune.co/investors/profile/invus) — VC Fund, 3 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 2 deals together
- [Emerson Collective](https://shizune.co/investors/profile/emerson-collective) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [SICTIC](https://shizune.co/investors/profile/sictic) — VC Fund
- [Zürcher Kantonal Bank](https://shizune.co/investors/profile/z%C3%BCrcher-kantonalbank) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund

## Featured in investor lists
- [Life Science Investors in Switzerland](https://shizune.co/investors/life-science-investors-switzerland)
- [Medical Device Investors in Switzerland](https://shizune.co/investors/medical-device-investors-switzerland)

## FAQ

### What does Bruker invest in?

Bruker invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Bruker?

Public channels for Bruker include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Bruker?

The team at Bruker includes Erez Sokolski (Project Manager), Frank Laukien (President & CEO) and Hermann Requardt (Member of the Board of Directors), among 11 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co